Alexander Spira, MD, PhD, Discusses Approval of Agents to Treated NSCLC With Exon 20 Insertion Mutations

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about future indications of mobocertinib.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how an FDA approval of mobocertinib [TAK-788] could positivity impact patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations. 

Transcript:

Right now, there are no future trials looking at [mobocertinib in patients previously treated with EGFR inhibitor] specifically. In the United States, we have an approved drug amivantamab [Rybrevant] for [EGFR] exon 20 insertion–mutant non-small cell lung cancer, which is a very different approach. It’s a monoclonal antibody versus mobocertinib, and the others described, which are small molecule TKIs. What we’ll all be interested to see is if you give mobocertinib first and they respond to amivantamab, or if you give amivantimab first, will they respond to mobocertinib. So [providers] think that’s where the field is going right now. In terms of TKIs, it’s likely that we will see mobocertinib approved in the short term—or at least, we hope we will in the United States—giving us that armamentarium. Whether the other TKIs play in at this point remains to be seen.